BiotechTube
Harvard Bioscience

Harvard Bioscience

HBIO
Holliston, United States· Est.
harvardbioscience.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

HBIO · Stock Price

USD 6.79+3.59 (+112.19%)
Market Cap: $32.2M

Historical price data

Overview

Harvard Bioscience (HBIO) is a 120+ year-old provider of essential research tools, serving as a foundational partner to the global life science R&D ecosystem. The company's strategy focuses on developing high-precision, niche instruments in electrophysiology, spectrophotometry, and data acquisition to accelerate therapeutic discovery and safety assessment. Recent achievements include the launch of innovative platforms like the INCUB8™ Multiwell MEA System and a strategic focus on operational efficiency to drive growth and margin improvement.

Medical DevicesResearch Tools

Technology Platform

A portfolio of high-precision instrument platforms for electrophysiology, spectrophotometry, and in vivo data acquisition, enabling life science research and preclinical testing.

Opportunities

Growth is driven by increased life science R&D spending, demand for integrated translational research tools like the INCUB8 MEA system, and expansion in bioprocessing quality control.
The company's niche expertise provides a defensible position against larger competitors.

Risk Factors

Key risks include its micro-cap valuation and stock volatility, intense competition from larger life science tool conglomerates, and reliance on customer capital expenditure budgets which are sensitive to economic and funding cycles.

Competitive Landscape

Competes in niche segments against giants like Thermo Fisher and Danaher, as well as specialized players like Molecular Devices (electrophysiology) and ADInstruments (in vivo physiology). Its strategy relies on technical depth and workflow innovation rather than scale.

More companies in Diagnostics & Precision Medicine →More companies in United States →